IRAK3 and neoplasm: Tumor inoculation studies of IRAK-M deficient models showed resistant to melonoma and fibrosarcoma tumor growth suggesting enhanced anti-tumor function of effector lymphocytes in the absence of IRAK-M [5, 196, 198, 213, 214].